Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Researcher uncovers mechanisms involved in prognosis of acute myeloid leukemia

Researcher uncovers mechanisms involved in prognosis of acute myeloid leukemia

DNA method leads to more effective treatment of neuroblastoma in children

DNA method leads to more effective treatment of neuroblastoma in children

AAPS recognizes top scientists in pharmaceutical sciences

AAPS recognizes top scientists in pharmaceutical sciences

Novel method can determine how ready acute myeloid leukemia cells are to die

Novel method can determine how ready acute myeloid leukemia cells are to die

LLS symposium to review latest advances in blood cancer research

LLS symposium to review latest advances in blood cancer research

AACR conference to focus on scientific and lifestyle strategies for cancer prevention

AACR conference to focus on scientific and lifestyle strategies for cancer prevention

Researchers develop interference therapies to knock down gene that drives MCL

Researchers develop interference therapies to knock down gene that drives MCL

Feline leukemia virus becoming uncommon with lymphoma

Feline leukemia virus becoming uncommon with lymphoma

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Viewpoints: Romney's views on health care still mysterious; Treating the dying patient

Viewpoints: Romney's views on health care still mysterious; Treating the dying patient

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

NIH awards $2.1M grant to study possible ways to fight cancer

NIH awards $2.1M grant to study possible ways to fight cancer

Transplant recipients and lymphoma patients far likelier to develop melanoma

Transplant recipients and lymphoma patients far likelier to develop melanoma

New book on natural interventions for lung cancer

New book on natural interventions for lung cancer

CINJ physicians named among 2012 list of U.S. News Top Doctors

CINJ physicians named among 2012 list of U.S. News Top Doctors

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Loyola oncologist named ‘Heroes of Hope’ by Leukemia Research Foundation

Loyola oncologist named ‘Heroes of Hope’ by Leukemia Research Foundation

Haploidentical bone marrow transplants for sickle cell disease: an interview with Dr. Javier Bolaños Meade

Haploidentical bone marrow transplants for sickle cell disease: an interview with Dr. Javier Bolaños Meade

Adolescent and young cancer cost barriers: an interview with Anne Kirchhoff

Adolescent and young cancer cost barriers: an interview with Anne Kirchhoff

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.